Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

BioRestorative Therapies (BRTX) EBIT Margin (2016 - 2025)

Historic EBIT Margin for BioRestorative Therapies (BRTX) over the last 15 years, with Q3 2025 value amounting to 31432.3%.

  • BioRestorative Therapies' EBIT Margin fell 304532800.0% to 31432.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 3785.07%, marking a year-over-year decrease of 5793100.0%. This contributed to the annual value of 2881.59% for FY2024, which is 75578900.0% up from last year.
  • According to the latest figures from Q3 2025, BioRestorative Therapies' EBIT Margin is 31432.3%, which was down 304532800.0% from 1089.77% recorded in Q2 2025.
  • BioRestorative Therapies' EBIT Margin's 5-year high stood at 979.02% during Q3 2024, with a 5-year trough of 126537.95% in Q4 2022.
  • Over the past 5 years, BioRestorative Therapies' median EBIT Margin value was 16687.47% (recorded in 2023), while the average stood at 28300.69%.
  • In the last 5 years, BioRestorative Therapies' EBIT Margin tumbled by -804870200bps in 2021 and then skyrocketed by 1098504700bps in 2023.
  • Over the past 5 years, BioRestorative Therapies' EBIT Margin (Quarter) stood at 80185.34% in 2021, then plummeted by -58bps to 126537.95% in 2022, then surged by 87bps to 16687.47% in 2023, then surged by 63bps to 6212.8% in 2024, then crashed by -406bps to 31432.3% in 2025.
  • Its EBIT Margin stands at 31432.3% for Q3 2025, versus 1089.77% for Q2 2025 and 19230.14% for Q1 2025.